Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Iovance Biotherapeutics (IOVA) Depreciation & Amortization (IS) (2024 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Depreciation & Amortization (IS) for 5 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (IS) rose 3.98% to $9.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.6 million, a 102.69% increase, with the full-year FY2025 number at $35.9 million, down 4.43% from a year prior.
  • Depreciation & Amortization (IS) was $9.5 million for Q4 2025 at Iovance Biotherapeutics, up from $9.2 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (IS) ranged from a high of $9.5 million in Q4 2025 to a low of $9.2 million in Q4 2024.